P
PrimeGen Biotech
Privately held stem cell research company dedicated to optimizing the therapeutic potential of adult stem cells
About PrimeGen Biotech
PrimeGen US specializes in developing advanced stem cell therapies aimed at treating inflammatory diseases at the cellular level. The company focuses on isolating and utilizing pro-inflammatory elements present in target diseases to activate mesenchymal stem cells, which then perform an anti-inflammatory function when introduced into the body. This approach is particularly beneficial for conditions such as cirrhosis, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH), which are prevalent in the United States. PrimeGen US serves patients suffering from these chronic liver conditions, offering them a natural and innovative treatment option that promotes faster healing and improved liver function. The company operates in the healthcare and biotechnology market, leveraging its proprietary methods to create a unique value proposition. PrimeGen US generates revenue through the development and commercialization of its stem cell therapies, targeting both individual patients and healthcare providers. The business model is centered around research and development, clinical trials, and partnerships with medical institutions to bring its therapies to market.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2002
- Headquarters
- Santa Ana, United States
- Listing
- Listed
- Employees
- 16
- Open positions
- None listed
- Dealroom signal
- 63.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Molecular Biology, Regenerative Medicine, Spinout, Verified Unicorns and $1B Exits, Biotech and Pharma, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SPAC IPO✓Exit | Feb 2026 | $69M | $1.5B | DT Cloud Star Acquisition Corporation | ↗ |
| DEBT✓Debt | Aug 2016 | $400K | — | Undisclosed | — |
Growth signals
Latest recorded traffic for PrimeGen Biotech is 3.1K monthly website visits, up 2483.3% over the last three months. PrimeGen Biotech's team declined 5.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
DT Cloud Star Acquisition Corporation
Other known investors1 additional known investor
Rutgers university
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about PrimeGen Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See PrimeGen Biotech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.